Affiliation:
1. Kaohsiung Chang Gung Memorial Hospital
Abstract
Abstract
Purpose:The Barcelona Clinic Liver Cancer (BCLC) staging system has been recommended for prognostic prediction. However, prognosis is variable at different BCLC stages. We aimed to evaluate whether the radiographic tumor burden score (TBS) could be used to stratify prognosis in different BCLC stages.
Methods: Hepatocellular carcinoma (HCC) patients undergoing liver resection (LR) at BCLC-0, -A, or -B stage in our institution in 2007–2018 were divided into derivation and validation cohorts. Overall survival (OS) was analyzed according to the TBS and BCLC stage. TBS cutoff values for OS were determined with X-tile.
Results: Of the 749 patients in the derivation cohort, 138 (18.4%) had BCLC-0, 542 (72.3 %) BCLC-A, and 69 (9.2 %) BCLC-B HCC; 81 (10.8%) had a high TBS (> 7.9), 474 (63.3%) a medium TBS (2.6–7.9), and 194 (25.9%) a low TBS (< 2.6). OS worsened progressively with increasing TBS in the cohort (p< 0.001) and in BCLC-A (p = 0.04) and BCLC-B (p = 0.002) stages. Multivariate analysis showed that the TBS was associated with OS of patients with BCLC-A (medium vs. low TBS: hazard ratio [HR] = 2.390, 95% CI = 1.024–5.581, p = 0.04; high vs. low TBS: HR = 3.885, 95% CI =1.443–10.456, p = 0.007) and BCLC-B (high vs. medium TBS: HR = 2.542, 95% CI = 1.077–6.002, p = 0.033) HCC. The TBS could also be used to stratify the OS of patients in the validation cohort (p< 0.001).
Conclusion: The TBS could be used to stratify the OS of the entire cohort and BCLC stages A and B of HCC patients undergoing LR.
Publisher
Research Square Platform LLC
Reference40 articles.
1. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study;Global Burden of Disease Cancer Collaboration;JAMA Oncol,2019
2. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases;Marrero JA;Hepatology;,2018
3. Management of hepatocellular carcinoma;EASL Clinical Practice Guidelines;J Hepatol,2018
4. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study;Vitale A;J Hepatol,2015
5. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma;Pawlik TM;Liver Transpl,2005